Amicus Therapeutics Temettü
Temettü kriter kontrolleri 0/6
Amicus Therapeutics does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-1.6%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -1.6% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if FOLD's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if FOLD's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
| Amicus Therapeutics Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (FOLD) | n/a |
| Pazarın Alt %25'i (US) | 1.5% |
| Pazarın En İyi %25'i (US) | 4.5% |
| Sektör Ortalaması (Biotechs) | 2.2% |
| Analist tahmini (FOLD) (3 yıla kadar) | 0% |
Önemli Temettü: Unable to evaluate FOLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate FOLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate FOLD's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as FOLD has not reported any payouts.